Alterity Therapeutics Limited

Alterity reported no revenue for the period. It posted an operating loss of $8.6 million and net operating cash outflow of $7.3 million, both described as in line with expectations and budget. Cash was $35 million at December 31, supported by a fully subscribed $35 million capital raising. Management said the Michael J. Fox Foundation grant of nearly USD 500,000 will fall into full-year results. Looking ahead, the company expects to begin the ATH434 Phase II trial in the second half of this year, while continuing regulatory discussions in Europe and completing manufacturing, preclinical work, and site/country selection.

David Stamler framed the quarter as a period of meaningful development progress rather than financial scale, emphasizing ATH434’s advancing profile in MSA and the growing scientific validation around alpha-synuclein as a target. He highlighted independent animal data, favorable cardiac safety findings, and the launch of bioMUSE as key steps toward a better-designed Phase II program. He also pointed to the new patent estate and the PBT2 AMR opportunity as ways to broaden Alterity’s long-term pipeline.

Kathryn Andrews said the half-year results were in line with expectations, citing no revenue, an operating loss of $8.6 million, and net operating cash outflow of $7.3 million. She said cash was $35 million at December 31, boosted by a $35 million placement to Australian and international institutional and sophisticated investors that was fully subscribed. She added that the proceeds are funding ATH434 clinical development, including bioMUSE, the Phase II MSA trial, ongoing research and discovery, and working capital; she also noted the R&D tax incentive rebate eligibility is still under assessment.

In Q&A, management said ATH434 Phase II preparation is progressing according to plan, with FDA feedback already received and European regulatory advice expected in the near future. They said manufacturing, preclinical work, and site/country selection are underway and still point to a second-half launch. On PBT2, management acknowledged the prior FDA partial clinical hold and said any future clinical plan would need to address the earlier nonclinical issues; they also said the AMR path is not yet defined and may require nondilutive funding. They confirmed ongoing interest from large pharma and said they expect more ATH434 publications and conference presentations later this year.